IN SILICO STUDY OF YODIUM LEAF (JATROPHA MULTIFIDA LINN) ACTIVE COMPOUND AS ANTIBIOTIC FOR DIABETIC WOUNDS

Objective: In this study, an in silico test of 13 active compounds of leaf Jatropha multifida Linn. was carried out against the gyrase receptor (PDB ID: 2XCT). Methods: The methods include molecular docking, ADMET prediction, and a review of Lipinski's Rule of Five. Results: Molecular docking simulation results obtained three test compounds with free energy of binding (∆G) and inhibition constants (Ki) at active site A, which are lower than the comparison compound, ciprofloxacin (∆G-5.41 kcal/mol). The three compounds are C2 (multidione), C5 (citlalitrione), and C6 (cleomiscosin A) which have ΔG of-6.00,-6.90, and-5.56 kcal/mol. Based on ADMET prediction, compound C5 has better pharmacokinetics, pharmacodynamics, and toxic activities compared to ciprofloxacin. Conclusion: Therefore, C5 is the best active compound from J. multifida, which can be used as a candidate for new antibiotics in the treatment of diabetic wounds

Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19

The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19